Lead Sponsor

Remedy Pharmaceuticals, Inc.

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

•1. A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA) territory.
•2. A large hemispheric infarction defined as; lesion volume of 80 to 300 centimeters cubed (cm\^3) on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or computed tomography perfusion (CTP), or an Alberta Stroke Program Early CT Score (ASPECTS) of 1 to 5 with involvement of at least 2 defined cortical regions.
•3. Screening National Institutes of Health Stroke Scale (NIHSS) \>=10.
•4. At the time of randomization, and in the Investigator's judgement, it must be feasible for study drug treatment infusion to be initiated no later than 10 hours after time of symptom onset, if known, or the time last known normal.

•5. For participants who receive thrombectomy, inclusion into the study must be based on post-thrombectomy MRI-DWI.
•1. Participant is likely to have supportive care withdrawn on the first day.
•2. Commitment to decompressive craniectomy (DC) prior to enrollment.
•3. Evidence of concurrent infarction in the contralateral hemisphere sufficiently serious so as to affect functional outcome.

Related studies

NCT05600374 · Ischemic Stroke, Acute

NCT06658197 · Stroke, Ischemic, Stroke, Acute, and more

NCT02879123 · Stroke, Acute

NCT07253870 · Stroke, Stroke, Acute

NCT05338697 · Stroke, Stroke, Acute, and more

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction